|
A combined phase I/II study of a novel bicycle tumor-targeted immune cell agonist BT7480 in patients with nectin-4 associated advanced malignancies. |
| |
|
Consulting or Advisory Role - Basilea; Bicycle Therapeutics; Turning Point Therapeutics |
Research Funding - 3D Medicines (Inst); Abbvie (Inst); ADC Therapeutics (Inst); Amgen (Inst); Anheart Therapeutics (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); Biontech (Inst); Calithera Biosciences (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); F-star (Inst); Incyte (Inst); Jounce Therapeutics (Inst); Kezar Life Sciences (Inst); Lilly (Inst); Linnaeus Therapeutics (Inst); MabSpace Biosciences (Inst); MedImmune (Inst); Merck (Inst); Mersana (Inst); Mirati Therapeutics (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst); Syros Pharmaceuticals (Inst); Tempest Therapeutics (Inst); Treadwell Therapeutics (Inst) |
| |
|
Consulting or Advisory Role - Abbvie/Stemcentrx; AstraZeneca; Bayer; Bristol-Myers Squibb; G1 Therapeutics; Ipsen; Merck; Takeda |
Research Funding - Abbvie/Stemcentrx (Inst); Amgen (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Ipsen (Inst); Lilly/ImClone (Inst); Mirati Therapeutics (Inst); Regeneron (Inst); Seagen (Inst); Symphogen (Inst); Takeda (Inst); Tesaro (Inst); United Therapeutics (Inst) |
| |
|
Employment - Bicycle Therapeutics |
Stock and Other Ownership Interests - Bicycle Therapeutics |
Patents, Royalties, Other Intellectual Property - Bicycle Therapeutics |
| |
|
Employment - Bicycle Therapeutics; Ipsen |
Stock and Other Ownership Interests - GlaxoSmithKline; Ipsen |
| |
|
Employment - Abbvie; Bicycle Therapeutics |
Stock and Other Ownership Interests - Bicycle Therapeutics |
| |
|
Employment - Bicycle Therapeutics |
Stock and Other Ownership Interests - Bicycle Therapeutics |
Patents, Royalties, Other Intellectual Property - On multiple patents at Bicycle Therapeutics, Ra Pharmaceuticals (now UCB) and the Ohio State University |
Travel, Accommodations, Expenses - Bicycle Therapeutics |
| |
|
Employment - Bicycle Therapeutics |
Stock and Other Ownership Interests - Bicycle Therapeutics |
Patents, Royalties, Other Intellectual Property - Bicycle Therapeutics |
| |
|
Employment - Bicycle Therapeutics; Cygnal Therapeutics (I); Fog Pharmaceuticals (I) |
Stock and Other Ownership Interests - Bicycle Therapeutics; Cygnal Therapeutics (I); Fog Pharmaceuticals (I); Novartis |
Patents, Royalties, Other Intellectual Property - Bicycle Therapeutics |
| |
|
Employment - Bicycle Therapeutics; Epizyme (I); KSQ Therapeutics (I); Vertex |
Stock and Other Ownership Interests - Bicycle Therapeutics; Epizyme (I); KSQ Therapeutics (I); Vertex |
Travel, Accommodations, Expenses - Vertex |
| |
|
No Relationships to Disclose |
| |
|
Employment - Bicycle Therapeutics |
Leadership - Bicycle Therapeutics |
Stock and Other Ownership Interests - Bicycle Therapeutics |
| |
|
Consulting or Advisory Role - Ellipses Pharma; iOnctura; Kelun Pharmaceuticals/Klus Pharma; Molecular Partners; Peptomyc |
Research Funding - AADi (Inst); Amgen (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); BioAtla (Inst); BioMed Valley Discoveries (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); Cellestia Biotech (Inst); Curis (Inst); CytomX Therapeutics (Inst); Deciphera (Inst); Fore Biotherapeutics (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Hummingbird (Inst); Hutchison MediPharma (Inst); IDEAYA Biosciences (Inst); Kelun (Inst); Linnaeus Therapeutics (Inst); Loxo (Inst); Merck Sharp & Dohme (Inst); Merus (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Nuvation Bio (Inst); Pfizer (Inst); Roche (Inst); Spectrum Pharmaceuticals (Inst); Symphogen (Inst); Taiho Pharmaceutical (Inst); Takeda/Millennium (Inst); Tango Therapeutics (Inst); Vall d'Hebron Institute of Oncology/Cancer Core Europe (Inst); Yingli Pharma (Inst) |
Travel, Accommodations, Expenses - ESMO |
Other Relationship - Boxer Capital; Chinese University of Hong Kong; Tang Advisors; Vall d'Hebron Institute of Oncology/Ministerio De Empleo Y Seguridad Social |